Cytek Biosciences, Inc. — Form 8-K Summary
Business context and reporting period
This Form 8-K reports an executive appointment effective October 31, 2022. It is not a quarterly or annual financial-results filing and does not provide financial statements or operating-period results.
- Company: Cytek Biosciences, Inc., a Delaware corporation listed on Nasdaq under CTKB.
- Reported event: Appointment of Chris Williams as Chief Operating Officer, effective October 31, 2022.
- Filing signed: November 1, 2022.
Financial and compensation information
- Annual base salary: $395,000.
- Target annual bonus: 50% of base salary.
- One-time sign-on cash bonus: $100,000, refundable if Mr. Williams terminates employment within 12 months of starting.
- Equity award: $500,000, split equally between stock options and restricted stock units.
- Stock options vest over four years: 25% on the first anniversary and the remainder monthly thereafter, subject to continued service.
- RSUs: 25% vesting on November 18, 2023, with the remaining 75% vesting quarterly over the following three years, subject to continued service.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
Material changes versus the prior comparable period
The material change disclosed is the addition of a new Chief Operating Officer. The filing does not present comparative financial information or identify other changes in business performance.
Outlook, risks, contingencies, and unusual items
- Mr. Williams is eligible for the Company’s annual bonus program, 2021 Employee Stock Purchase Program, and Severance Benefit Plan.
- The Company will enter into its standard indemnification agreement with Mr. Williams, covering certain expenses and claims arising from his service as an officer, to the fullest extent permitted by law.
- The sign-on bonus is subject to repayment upon qualifying termination by Mr. Williams within the first 12 months.
- The equity awards create future stock-based compensation and dilution exposure; the filing does not quantify the related expense or share count.
- No family relationships or related-party transactions requiring disclosure under Item 404(a) were identified.
- The filing includes an offer letter dated October 4, 2022, and a related October 31, 2022 press release.
Key facts for investors to verify
- Review the complete offer letter for termination, change-in-control, vesting, and other employment terms.
- Verify the final number and exercise price of stock options and the number of RSUs granted.
- Assess the expected stock-based compensation expense and potential dilution from the $500,000 equity award.
- Review the Company’s subsequent filings for any changes in executive leadership, severance arrangements, or operating performance.